CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(01): 033-037
DOI: 10.4103/2278-330X.126516
FEMALE REPRODUCTIVE TRACT TUMORS : Original Article

Gestational trophoblastic neoplasia: A 6 year retrospective study

Sushruta Shrivastava
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Gopinath Nagar, Guwahati, Assam
,
Amal Chandra Kataki
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Gopinath Nagar, Guwahati, Assam
,
Debabrata Barmon
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Gopinath Nagar, Guwahati, Assam
,
Pankaj Deka
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Gopinath Nagar, Guwahati, Assam
,
Chidananda Bhuyan
Department of Medical Oncology, Dr. B. Borooah Cancer Institute (RCC), Gopinath Nagar, Guwahati, Assam
,
Saikia J. Bhargav
Department of Medical Oncology, Dr. B. Borooah Cancer Institute (RCC), Gopinath Nagar, Guwahati, Assam
› Author Affiliations
Source of Support: Nill.

Abstract

Aims and Objectives: To study the clinical presentations of gestational trophoblastic neoplasia and its response to chemotherapy. Materials and Methods: This is a retrospective study of 28 women of gestational trophoblastic neoplasia evaluated over a period of 6 years from January 2004 to December 2009. Patients were evaluated on the basis of their age, number of deliveries, history of abortion or molar pregnancy, and the treatment received. All patients were scored on the basis of WHO scoring system. Patients with low risk (score </=6) received single agent chemotherapy with methotrexate or actinomycin D. Patients with high risk (score >/=7) received multiple agent chemotherapy with EMACO regimen. After completion of chemotherapy patients were followed for a minimum of 2 years. The response to treatment was evaluated during follow-up by clinical examination, beta hCG levels and imaging as and when required. Results: Out of 28 women only 27 could be evaluated, because 1 patient was lost to follow-up. Out of 27 patients, 18 patients (66.67%) achieved complete remission with the first-line chemotherapy and additional 25.92% (7/27) achieved complete remission with second line chemotherapy resulting in complete remission of 92.5% (25/27). Conclusion: Gestational trophoblastic neoplasia is curable if patient is properly evaluated and scored. It shows good response to chemotherapy.



Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 ACOG Practice Bulletin 53. Diagnosis and treatment of gestational trophoblastic neoplasms. Obstet Gynecol 2004;103:1365-77.
  • 2 Homesley HD. Single agent therapy for non-metastatic and low risk metastatic gestational trophoblastic disease. J Reprod Med 1998;43:69-74.
  • 3 Szigetvagi I, Szepesi J, Vegh G, Bátorfi J, Arató G, Gáti I, et al. 25 years′ experience in the treatment of gestational trophoblastic neoplasia in Hungary. J Reprod Med 2006;51:841-8.
  • 4 Lurain JR, Singh DC, Schink JC. Primary treatment of metastatic high risk gestational trophoblastic neoplasms with EMA-CO chemotherapy. J Reprod Med 2006;51:767-72.
  • 5 Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L, Dent J. Developments in chemotherapy for medium and high risk patients with gestational trophoblastic tumors (1979-1984). Br J Obstet Gynaecol 1986;93:63-9.
  • 6 Goldstein DP, Berkowitz RS. Gestational Trophoblastic Diseases. In: Vincent T, Lawrence, Theodore S, Rosenberg, Steven A, editors. Cancer: Principles and Practice of Oncology. North America: Lippincott Williams and Wilkins; 2008. p. 1564-8.
  • 7 Berkowitz RS, Goldstein DP. Gestational Trophoblastic Neoplasia.In: Berek JS, Hacker NF, editors. Practical Gynecologic Oncology. Baltimore: Williams and Wilkins; 1989. p. 441-68.
  • 8 Bafna UD, Ahuja VK, Umadevi K, Srinivasan N, Mani K, Vallikad E. Gestational trophoblastic tumors - situation analysis in a third world regional cancer center. Int J Gynecol Cancer 1997;7:197-204.
  • 9 Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al. EMA/CO for high risk gestational trophoblastic tumors: Results from a cohort of 272 patients. J Clin Oncol 1997;15:2636-43.
  • 10 Bolis G, Bonazzi C, Landoni F, Mangili G, Vergadoro F, Zanaboni F, et al. EMA/CO regimen in hich-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 1988;31:439-44.
  • 11 Soper JT. Staging and evaluation of gestational trophoblastic disease. Clin Obstet Gynecol 2003;46:570-8.